Johnson & Johnson (JNJ) Accumulated Depreciation & Amortization (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Accumulated Depreciation & Amortization came in at $2.0 billion in Q1 2026, up 13.09% year-on-year from $1.8 billion in Q1 2025, and down 73.29% quarter-over-quarter from $7.5 billion in Q4 2025.

Johnson & Johnson (JNJ) Accumulated Depreciation & Amortization (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Accumulated Depreciation & Amortization across 18 years of filings, most recently posting $2.0 billion for Q1 2026.

  • Accumulated Depreciation & Amortization for Q1 2026 came in at $2.0 billion, up 13.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 billion (up 13.09% YoY), and the FY2025 annual result was $7.5 billion, up 2.23% from the prior year.
  • Accumulated Depreciation & Amortization came in at $2.0 billion for Q1 2026 at Johnson & Johnson, down from $7.5 billion in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $7.5 billion in Q4 2025 to a low of $1.8 billion in Q2 2022.
  • The 5-year median for Accumulated Depreciation & Amortization is $4.5 billion (2022), against an average of $4.6 billion.
  • Across the five-year window, Accumulated Depreciation & Amortization decreased 6.6% in 2022 and climbed 13.09% in 2026, its largest moves.
  • Johnson & Johnson's Accumulated Depreciation & Amortization stood at $5.2 billion in 2022, then soared by 44.02% to $7.5 billion in 2023, then slipped by 1.96% to $7.3 billion in 2024, then gained by 2.23% to $7.5 billion in 2025, then sank by 73.29% to $2.0 billion in 2026.
  • The last three Accumulated Depreciation & Amortization figures came in at $2.0 billion (Q1 2026), $7.5 billion (Q4 2025), and $5.5 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 29, 2026 2.00 Bn
Mar 29, 2026 2.00 Bn
Dec 28, 2025 7.50 Bn
Dec 28, 2025 7.50 Bn
Sep 28, 2025 5.49 Bn
Sep 28, 2025 5.49 Bn
Jun 29, 2025 3.72 Bn
Jun 29, 2025 3.72 Bn
Mar 30, 2025 1.77 Bn
Mar 30, 2025 1.77 Bn
Dec 29, 2024 7.34 Bn
Dec 29, 2024 7.34 Bn
Sep 29, 2024 5.44 Bn
Sep 29, 2024 5.44 Bn
Jun 30, 2024 3.60 Bn
Jun 30, 2024 3.60 Bn
Mar 31, 2024 1.82 Bn
Mar 31, 2024 1.82 Bn
Dec 31, 2023 7.49 Bn
Dec 31, 2023 7.49 Bn